According to Shanwaishan's announcement, Hunan Xiangjiang Health Venture Capital Partnership, which holds more than 5% of the company's shares, and its co-actor, Hunan Xiangjiang Liyuan Jiankun Venture Capital Partnership, will reduce their holdings of the company's shares by 4.5 million shares through bulk transactions between September 3 and September 15, 2026, accounting for 1.01% of the company's total share capital. After this change in equity, the total shareholding ratio of the two was reduced from 9.00% to 7.99%. This change did not violate relevant commitments and did not trigger mandatory tender offer obligations.

According to Shanwaishan's announcement, Hunan Xiangjiang Health Venture Capital Partnership, which holds more than 5% of the company's shares, and its co-actor, Hunan Xiangjiang Liyuan Jiankun Venture Capital Partnership, will reduce their holdings of the company's shares by 4.5 million shares through bulk transactions between September 3 and September 15, 2026, accounting for 1.01% of the company's total share capital. After this change in equity, the total shareholding ratio of the two was reduced from 9.00% to 7.99%. This change did not violate relevant commitments and did not trigger mandatory tender offer obligations.